Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference

Rhea-AI Summary

Alterity Therapeutics (NASDAQ: ATHE, ASX: ATH) announced that CEO David Stamler, M.D., will present at the 46th Annual Canaccord Genuity Growth Conference on Tuesday, August 11, 2026 at 1:30 p.m. ET in the United States.

A live and archived webcast of the presentation will be available via the Investors > Events and Presentations section of Alterity’s website. Alterity is a clinical-stage biotechnology company focused on disease-modifying therapies for Multiple System Atrophy (MSA) and related Parkinsonian disorders, with lead asset ATH434 having shown clinically meaningful efficacy in a Phase 2 trial.

Market Context

The prior conference notice, news_id 1084309, was followed by a 5.06% 24-hour move, supplying the cl...

Analysis

The prior conference notice, news_id 1084309, was followed by a 5.06% 24-hour move, supplying the closest comparison. Clinical announcements varied from -6.79% to 9.44%; low short positioning was additional context, not a forecast.

Key Figures

Conference edition: 46th annual Announcement date: August 06, 2026 Presentation date: August 11, 2026 +4 more

7 metrics

Conference edition 46th annual Canaccord Genuity Growth Conference

Announcement date August 06, 2026 Article publication

Presentation date August 11, 2026 Canaccord Genuity Growth Conference

Presentation time 1:30 p.m. ET United States presentation

Planned trial phase Phase 3 Pivotal trial in Multiple System Atrophy

Prior trial phase Phase 2 Randomized, double-blind, placebo-controlled clinical trial

Additional trial phase Phase 2 Open-label clinical trial in advanced MSA

Historical Context

5 past events · Latest: Jul 21 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 21	Conference participation	Neutral	+5.1%	CEO scheduled investor meetings at the virtual BTIG Biotechnology Conference
Jul 07	FDA pathway update	Positive	-6.8%	FDA minutes confirmed a registrational pathway for ATH434
Jun 09	FDA program alignment	Positive	+9.4%	FDA aligned with the pivotal Phase 3 program design
May 19	Phase 3 advancement	Positive	-1.5%	Phase 2 analyses supported advancing ATH434 into Phase 3
May 11	MRI biomarker publication	Positive	+3.0%	Peer-reviewed publication described QSM MRI biomarker utility

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The prior conference-participation announcement was followed by a positive reaction, while clinical announcements produced mixed reactions.

Key Terms

multiple system atrophy, double-blind, placebo-controlled, open label

4 terms

multiple system atrophy medical

"therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders"

A progressive neurological disorder that damages multiple areas of the nervous system, causing problems with movement, balance and involuntary functions like blood pressure and bladder control; think of it as critical wiring in the body slowly failing. Investors care because the condition defines the size and urgency of the market for treatments, influences clinical trial difficulty and regulatory risk, and can lead to high per-patient pricing but also greater development uncertainty.

double-blind medical

"a randomized, double-blind, placebo-controlled Phase 2 clinical trial"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"a randomized, double-blind, placebo-controlled Phase 2 clinical trial"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

open label medical

"positive data in its open label Phase 2 clinical trial"

Open label is a clinical trial design in which both the participants and the researchers know which treatment or intervention is being given. For investors, this matters because knowledge of the treatment can influence reported effects and side effects—like how seeing a product label can change a shopper’s opinion—so open-label results are useful for safety and real-world experience but are generally viewed as less rigorous evidence of effectiveness than blinded studies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MELBOURNE, Australia and SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will present at the 46^th Annual Canaccord Genuity Growth Conference on Tuesday, August 11, 2026 at 1:30 p.m. ET in the United States.

A link to the live and archived webcast may be accessed on Alterity Therapeutics website under the Investors section: Events and Presentations.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.

Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Contacts:

Investors
Elyse Shapiro
ir@alteritytx.com

Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386

Media
Melissa Tempra
NWR Communications
melissa@nwrcommunications.com.au

Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

FAQ

When will Alterity Therapeutics (NASDAQ: ATHE) present at the 46th Annual Canaccord Genuity Growth Conference?

Alterity Therapeutics will present on Tuesday, August 11, 2026 at 1:30 p.m. ET. According to Alterity Therapeutics, CEO David Stamler, M.D., will deliver the presentation as part of the 46th Annual Canaccord Genuity Growth Conference held in the United States.

How can investors access the Alterity Therapeutics (ATHE) webcast from the Canaccord Genuity Growth Conference 2026?

Investors can access a live and archived webcast via Alterity Therapeutics’ website under the Investors > Events and Presentations section. According to Alterity Therapeutics, both real-time and replay viewing will be available for the conference presentation by CEO David Stamler.

What is Alterity Therapeutics’ lead clinical asset ATH434 mentioned in the August 2026 ATHE conference update?

ATH434 is Alterity Therapeutics’ lead asset for treating Multiple System Atrophy (MSA). According to Alterity Therapeutics, ATH434 demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in MSA participants and showed positive data in an open-label Phase 2 trial in advanced MSA.

What stage is Alterity Therapeutics’ Multiple System Atrophy (MSA) program as of August 2026?

Alterity Therapeutics is preparing to initiate a Phase 3 pivotal trial in Multiple System Atrophy. According to Alterity Therapeutics, the company has already completed Phase 2 studies in MSA with ATH434 and reported clinically meaningful efficacy and additional positive data in participants with advanced disease.

What therapeutic areas does Alterity Therapeutics (ATHE) focus on as described in its August 2026 conference announcement?

Alterity Therapeutics focuses on neurodegenerative diseases, particularly Multiple System Atrophy and related Parkinsonian disorders. According to Alterity Therapeutics, it is a clinical-stage biotechnology company developing disease-modifying therapies and using a drug discovery platform to generate patentable compounds targeting neurological disease pathology.

Where is Alterity Therapeutics headquartered according to its August 2026 investor communication?

Alterity Therapeutics is based in Melbourne, Australia and San Francisco, California, USA. According to Alterity Therapeutics, these locations support its clinical-stage biotechnology operations focused on developing disease-modifying treatments for neurodegenerative diseases, including Multiple System Atrophy and related Parkinsonian disorders.